U.O. Oncologia 2 Universitaria A.O.U. Pisana
Welcome,         Profile    Billing    Logout  
 4 Trials 
4 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pedersini, Rebecca RP
NCT06137833: Wide Spectrum Micronutrients Supplementation in Patients with Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy

Recruiting
N/A
92
Europe
APPOPRTAL®, Placebo
Pharmanutra S.p.a., Latis S.r.l.
Fatigue, Breast Cancer
06/25
06/25
Fontana, Andrea
FOENIX-MBC2 TAS-120-201, NCT04024436 / 2019-001164-30: A Study of TAS-120 in Patients With Metastatic Breast Cancer

Completed
2
168
Europe, Canada, US
Futibatinib, TAS-120, Futibatinib plus Fulvestrant
Taiho Oncology, Inc., Taiho Pharma Europe Limited, TAIHO ONCOLOGY INC.
Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification
05/23
10/24
NCT06137833: Wide Spectrum Micronutrients Supplementation in Patients with Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy

Recruiting
N/A
92
Europe
APPOPRTAL®, Placebo
Pharmanutra S.p.a., Latis S.r.l.
Fatigue, Breast Cancer
06/25
06/25
NCT05754502: Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Recruiting
N/A
300
Europe
Trastuzumab emtansine
Consorzio Oncotech, Roche Pharma AG
Breast Cancer
09/24
05/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pedersini, Rebecca RP
NCT06137833: Wide Spectrum Micronutrients Supplementation in Patients with Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy

Recruiting
N/A
92
Europe
APPOPRTAL®, Placebo
Pharmanutra S.p.a., Latis S.r.l.
Fatigue, Breast Cancer
06/25
06/25
Fontana, Andrea
FOENIX-MBC2 TAS-120-201, NCT04024436 / 2019-001164-30: A Study of TAS-120 in Patients With Metastatic Breast Cancer

Completed
2
168
Europe, Canada, US
Futibatinib, TAS-120, Futibatinib plus Fulvestrant
Taiho Oncology, Inc., Taiho Pharma Europe Limited, TAIHO ONCOLOGY INC.
Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification
05/23
10/24
NCT06137833: Wide Spectrum Micronutrients Supplementation in Patients with Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy

Recruiting
N/A
92
Europe
APPOPRTAL®, Placebo
Pharmanutra S.p.a., Latis S.r.l.
Fatigue, Breast Cancer
06/25
06/25
NCT05754502: Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Recruiting
N/A
300
Europe
Trastuzumab emtansine
Consorzio Oncotech, Roche Pharma AG
Breast Cancer
09/24
05/25

Download Options